2-(6-chloro-2-(p-tolyl)imidazo[1,2-b]pyridazin-3-yl)-N,N-dipropylacetamide

ID: ALA5272616

Chembl Id: CHEMBL5272616

Max Phase: Preclinical

Molecular Formula: C21H25ClN4O

Molecular Weight: 384.91

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCN(CCC)C(=O)Cc1c(-c2ccc(C)cc2)nc2ccc(Cl)nn12

Standard InChI:  InChI=1S/C21H25ClN4O/c1-4-12-25(13-5-2)20(27)14-17-21(16-8-6-15(3)7-9-16)23-19-11-10-18(22)24-26(17)19/h6-11H,4-5,12-14H2,1-3H3

Standard InChI Key:  QYXGEANURIDDCJ-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5272616

    ---

Associated Targets(Human)

GABRA1 Tclin GABA receptor alpha-1 subunit (399 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GABRA2 Tclin GABA receptor alpha-2 subunit (271 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 384.91Molecular Weight (Monoisotopic): 384.1717AlogP: 4.55#Rotatable Bonds: 7
Polar Surface Area: 50.50Molecular Species: NEUTRALHBA: 4HBD:
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 2.02CX LogP: 4.98CX LogD: 4.98
Aromatic Rings: 3Heavy Atoms: 27QED Weighted: 0.60Np Likeness Score: -1.76

References

1. Garrido A, Vera G, Delaye PO, Enguehard-Gueiffier C..  (2021)  Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry: An extensive review.,  226  [PMID:34607244] [10.1016/j.ejmech.2021.113867]

Source